

Author's Accepted Manuscript

Immunologic Checkpoint Blockade in Lung Cancer

Martin Reck MD, PhD, Luis Paz-Ares MD, PhD



www.elsevier.de/endum

PII: S0093-7754(15)00029-9
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2015.02.013>
Reference: YSONC51816

To appear in: *Semin Oncol*

Cite this article as: Martin Reck MD, PhD, Luis Paz-Ares MD, PhD, Immunologic Checkpoint Blockade in Lung Cancer, *Semin Oncol*, <http://dx.doi.org/10.1053/j.seminoncol.2015.02.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Immunologic Checkpoint Blockade in Lung Cancer

Martin Reck, MD, PhD^a and Luis Paz-Ares, MD, PhD^b

^aDepartment of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), member of the German center for Lung research (DZL), Grosshansdorf, Germany; ^bDepartment of Medical Oncology, Instituto de Biomedicina de Sevilla – IBIS (Hospital Universitario Virgen del Rocio, Universidad de Sevilla and CSIC), Seville, Spain.

Corresponding author:

Martin Reck

Department of Thoracic Oncology,

LungenClinic Grosshansdorf

Wöhrendamm 80, 22927

Grosshansdorf, Germany

Email: m.reck@lungenclinic.de

Tel.: +49 4102 601 2101; fax: +49 4102 601 7101

Acknowledgments: The authors take full responsibility for the content of this publication, and confirm that it reflects their collective viewpoint and medical expertise. StemScientific, funded by Bristol-Myers Squibb, provided writing and editing support. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.

Conflicts of interest: Martin Reck has received honoraria for the participation in advisory boards and for lectures from Hoffmann-La Roche, Lilly, Boehringer-Ingelheim, Pfizer,

Download English Version:

<https://daneshyari.com/en/article/2161827>

Download Persian Version:

<https://daneshyari.com/article/2161827>

[Daneshyari.com](https://daneshyari.com)